Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration. This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast. To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year. “At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.” “If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”